Treatment of ALK+ lung cancer with crizotinib, Profile 1007

The first phase II trial for the management of oesophageal cancer

Phase III MISSION trial: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer

Personalised cancer medicine and research: Today’s best practice

Treating liver metastases in colorectal cancer

Putting drugs to work against brain metastases in HER2 positive breast cancer: LANDSCAPE study

The Multinational Association of Supportive Care in Cancer (MASCC)

Defining personalised medicine and patient empowerment

Phase I study examining PI 3 kinase inhibitor for various tumours

Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer

A proof-of-concept study of ODM-201 in patients with progressive castration-resistant prostate cancer

Too few women being offered breast-conserving treatment?